THERAPEUTIC SIMPLIFICATION WITH THYMIDINE ANALOGUR SPARING REGIMENS IN PATIENTS ON EFFECTIVE HAART: A CONTROLLED, RANDOMIZED STUDY

INTERVENTION: Pharmaceutical Form: Capsule, hard INN or Proposed INN: Zidovudine CAS Number: 30516‐87‐1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Pharmaceutical Form: Capsule, hard INN or Proposed INN: Stavudine CAS Number: 3056‐17‐5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20‐ Pharmaceutical Form: Gastro‐resistant capsule, hard INN or Proposed INN: Didanosine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400‐ Pharmaceutical Form: Tablet INN or Proposed INN: Lamivudine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150‐ Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: Zalcitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .75‐ Trade Name: ZIAGEN*6BLISTER 10CPR 300MG Pharmaceutical Form: Coated tablet INN or Proposed INN: Abacavir Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300‐ Trade Name: VIREAD*30CPR 245MG Pharmaceutical Form: Tablet INN or Proposed INN: Tenofovir disoproxil Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 245‐ CONDITION: TREATMENT HIV PRIMARY OUTCOME: Main Objective: Primary end point(s): Secondary Objective: INCLUSION CRITERIA: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range